Glucosylceramide Synthase

Glucosylceramide Synthase

The first reaction of ceramide glycosylation in sphingolipid metabolism is catalyzed by glucosylceramide synthase (GCS), which changes ceramide into glucosylceramide. By regulating ceramide and glycosphingolipids (GSLs), this glycosylation by GCS is a crucial step in controlling the modulation of cellular activities.Ceramide levels rise in response to stresses like chemotherapy, which causes cells to enter apoptosis or autophagy. Ceramide glycosylation, however, quickly removes ceramide and, as a result, these induced processes, protecting cancer cells. Additionally, persistently increased ceramide glycosylation can raise GSLs and contribute to the selection of drug-resistant cancer cells. In numerous drug-resistant cancer cells as well as breast, colon, and leukemia tumors that exhibit a poor response to chemotherapy, GCS is overexpressed. Inhibition of GCS makes cancer cells more susceptible to anticancer medications and kills cancer stem cells because ceramide glycosylation by GCS is a rate-limiting step in GSL synthesis.

Glucosylceramide Synthase related products

Structure Cat No. Product Name CAS No. Product Description
V70294 D-threo-PDMP 109836-82-0
V70297 D-threo-PPMP 139889-53-5
V70295 D-threo-PPMP hydrochloride 139889-65-9
V79532 Fucosyltransferase 8 (EC:2.4.1.68; FUT8; α1-6FucT)
V3367 Ibiglustat 1401090-53-6 Ibiglustat (formerly Venglustat; SAR-402671; GZ-402671; GZ-452; Genz-682452) is a novel, brain-penetrant, potent and selective allosteric Glucosylceramide synthase (GCS) inhibitor and ceramide glucosyltransferase inhibitor.
V32453 Ibiglustat L-Malic acid 1629063-78-0 Ibiglustat L-Malic acid(Venglustat; GZ402671;Genz-682452;GZ-452; SAR-402671)is a novel and potent inhibitor of glucosylceramide synthase (GCS) and also aceramide glucosyltransferase inhibitor.
V70296 Ibiglustat succinate (Venglustat succinate; SAR402671 succinate; GZ402671 succinate) 1629063-80-4
V25528 Miglustat HCl (OGT-918; NB-DNJ; Zavesca) 210110-90-0 Miglustat HCl (OGT-918;NB-DNJ;Zavesca)is an FDA approved drug used to treatType I Gaucher disease (GD1).
V70293 Nizubaglustat 1633666-49-5
V81662 UDP-GalNAc:β-1,3-N-acetylgalactosaminyltransferase 2 (EC:2.4.1.313; B3GALNT2; β-1,3-N-acetylgalactosaminyltransferase II)
V81797 α-N-Acetylglucosaminidase (EC:3.2.1.50; NAGLU; UFHSD 1)
Contact Us